About Naveris
Naveris: Revolutionizing Cancer Detection with Liquid Biopsies
Cancer is one of the deadliest diseases in the world, and early detection is crucial for successful treatment. However, traditional cancer screening methods such as scans and biopsies are often invasive, expensive, and not always accurate. This is where Naveris comes in - a company that has developed highly sensitive blood tests known as liquid biopsies that can identify viral cancers significantly earlier than traditional methods.
Naveris was founded by a team of experienced scientists who recognized the need for more accurate and less invasive cancer screening methods. They have spent years researching and developing liquid biopsy technology that can detect even small amounts of cancer DNA in a patient's blood sample.
The liquid biopsy test developed by Naveris works by analyzing circulating tumor DNA (ctDNA) in the bloodstream. ctDNA is released into the bloodstream when cancer cells die or divide, making it an excellent indicator of cancer presence. The test can detect ctDNA from various types of cancers, including lung, breast, colon, prostate, ovarian cancers among others.
One significant advantage of Naveris' liquid biopsy test over traditional biopsies is its non-invasive nature. Unlike traditional biopsies which require tissue samples to be taken from affected areas using needles or surgery; liquid biopsies only require a simple blood draw from patients.
Another advantage of Naveris' technology over other existing diagnostic tools like CT scans or MRIs is its ability to detect early-stage cancers before they become visible on imaging tests like CT scans or MRIs. Early detection means earlier intervention which increases chances for successful treatment outcomes.
Naveris' innovative approach to detecting viral cancers has garnered attention from both medical professionals and investors alike. The company has received funding from several venture capital firms including Sequoia Capital and Khosla Ventures among others.
In addition to their groundbreaking work on liquid biopsies for viral cancers, Naveris is also working on developing tests for other diseases such as Alzheimer's and Parkinson's. Their goal is to revolutionize the way we diagnose and treat diseases by providing accurate, non-invasive diagnostic tools that can detect diseases at their earliest stages.
In conclusion, Naveris is a company that has made significant strides in the field of cancer detection with its innovative liquid biopsy technology. Their non-invasive approach to detecting viral cancers has the potential to save countless lives by enabling earlier intervention and treatment. With ongoing research into other disease areas, Naveris is poised to become a leader in the field of diagnostic medicine.